



## Immunotherapy and Transplantation in the Era of Transplant Oncology

Guest Editors:

**Dr. Maen Abdelrahim**

**Dr. Ala Abudayyeh**

**Dr. Abdullah Esmail**

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editors

Dear Colleagues,

Immune-checkpoint inhibitor (ICPI) therapies have shown excellent responses with tolerable side effects in the treatment of different cancers. However, our knowledge and experience in the use of immunotherapy in solid organ transplant recipients and candidates are limited.

The use of immunotherapy in liver pre-transplant patients as bridging therapy, and as palliative therapy in post-transplant patients to treat cancer recurrence or second primary cancer, is an area of unmet need. Transplant patients have been excluded from ICPI clinical trials due to concern for autograft rejection. In the last five years, retrospective studies and limited prospective trials have shown the possibility of using ICPIs in this patient population. This field of transplant oncology is currently being investigated. Our Special Issue will highlight the current state of the utilization of ICPI therapies in pre- and post-liver and other solid organ transplants, and will discuss the assessment of safety and response biomarkers.

Dr. Maen Abdelrahim

Dr. Ala Abudayyeh

Dr. Abdullah Esmail





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI